摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-butyl-9,9-dimethyl-2,4,6, 8-tetraoxo-3,7-diazabicyclo[3,3,1]nonane | 90961-81-2

中文名称
——
中文别名
——
英文名称
3-butyl-9,9-dimethyl-2,4,6, 8-tetraoxo-3,7-diazabicyclo[3,3,1]nonane
英文别名
3-butyl-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone
3-butyl-9,9-dimethyl-2,4,6, 8-tetraoxo-3,7-diazabicyclo[3,3,1]nonane化学式
CAS
90961-81-2
化学式
C13H18N2O4
mdl
——
分子量
266.297
InChiKey
OLXXSWCYGOQRLD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.69
  • 拓扑面积:
    83.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    SCHOEN, U.;HACHMEISTER, B.;KEHRBACH, W.;KUEHL, U.;BUSCHMANN, G.
    摘要:
    DOI:
  • 作为产物:
    描述:
    1-Butyl-4,4-dimethyl-2,6-dioxo-piperidine-3,5-dicarbonitrile 在 磷酸硫酸 作用下, 以56%的产率得到3-butyl-9,9-dimethyl-2,4,6, 8-tetraoxo-3,7-diazabicyclo[3,3,1]nonane
    参考文献:
    名称:
    Synthesis, Pharmacological Characterization, and Quantitative Structure−Activity Relationship Analyses of 3,7,9,9-Tetraalkylbispidines:  Derivatives with Specific Bradycardic Activity
    摘要:
    A series of 3,7,9,9-tetraalkyl-3,7-diazabicyclo[3.3.1]nonane derivatives (bispidines) was synthesized and identified as potential antiischemic agents. Pharmacological experiments in vitro as well as in vivo are described, and the results are listed. For selection of those compounds fitting best to the desired profile of a specific bradycardic antianginal agent-decrease in heart rate without affecting contractility and blood pressure-these results were scored and ranked. Quantitative structure-activity relationship (QSAR) analyses were performed and discussed a posteriori by means of Hansch, nonelementary discriminant and factor analysis to get insight into the molecular features determining the biological profile. Highly significant equations were obtained, indicating hydrophobic and steric effects. Both pharmacological ranking and QSAR considerations showed compound 6 as the optimum within the structural class under investigation. Compound 6 (tedisamil, KC8857) has been selected as the most promising compound and was chosen for further pharmacological and clinical investigations as an antiischemic drug.
    DOI:
    10.1021/jm970120q
点击查看最新优质反应信息

文献信息

  • PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES
    申请人:Johnson Matthey Public Limited Company
    公开号:US20150361099A1
    公开(公告)日:2015-12-17
    Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.
    用于制备通式(I)和(VII)中所示的烷基化芳基哌嗪和烷基化芳基哌啶化合物的新工艺和中间体,其中,R1和R2分别选择自氢、烷基、取代基或烷基;n=0、1或2;Y=NR3R4、OR5或SR5,其中R3和R4分别选择自酰基或磺酰基,R5是芳基或杂芳基,或杂环烷基;Ar是芳基、杂芳基或杂环烷基。
  • Method of diuretic treatment with 3,7-diazabicyclo[3,3,1]nonane compounds
    申请人:Kali-Chemie Pharma GmbH
    公开号:US05164401A1
    公开(公告)日:1992-11-17
    A method of treating a mammal in need of diruetic treatment by administering an effective diuretic amount of a diuretically active 3,7,9,9-tetrasubstituted 3,7-diazabicyclo[3,3,1]nonane compound, diuretic pharmaceutical compositions containing an effective diuretic amount of a diuretically active 3,7,9,9-tetrasubstituted 3,7-diazabicyclo[3,3,1]nonane compound; and previously unknown diuretically active 3,7,9,9-tetrasubstituted 3,7-diazabicyclo[3,3,1]nonane compounds containing an optionally substituted phenylalkyl group in the 3-position.
    治疗需要利尿治疗的哺乳动物的方法是通过给予具有利尿活性的3,7,9,9-四取代3,7-二氮杂双环[3,3,1]壬烷化合物的有效利尿量进行治疗,包含有效利尿量的具有利尿活性的3,7,9,9-四取代3,7-二氮杂双环[3,3,1]壬烷化合物的利尿药物组合物;以及先前未知的具有利尿活性的3,7,9,9-四取代3,7-二氮杂双环[3,3,1]壬烷化合物,其中在3-位置含有可选择取代的苯基烷基基团。
  • SCHON, UWE;KEHRBACH, WOLFGANG;WOLF, KLAUS-ULLRICH
    作者:SCHON, UWE、KEHRBACH, WOLFGANG、WOLF, KLAUS-ULLRICH
    DOI:——
    日期:——
  • SCHON, UWE;KEHRBACH, WOLFGANG;BUSCHMANN, GERD;KUHL, ULRICH;ZIEGLER, DIETE+
    作者:SCHON, UWE、KEHRBACH, WOLFGANG、BUSCHMANN, GERD、KUHL, ULRICH、ZIEGLER, DIETE+
    DOI:——
    日期:——
  • SCHON, U.;KEHRBACH, W.;BUSCHMANN, G.;KUHL, U.;ZIEGLER, D.
    作者:SCHON, U.、KEHRBACH, W.、BUSCHMANN, G.、KUHL, U.、ZIEGLER, D.
    DOI:——
    日期:——
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺